drugset

drugset / Trial / NCT06390410

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

NCT06390410 ↗

Phase 1 Completed 27 enrolled Cassava Sciences, Inc.

Non-randomizedParallel-groupOpen-labelBasic science

Summary

Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics

Timeline

Start: 2024-06-26
Primary completion: 2024-12-07
Completion: 2024-12-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Simufilam	Small molecule	100 mg	—

Indications